VRNG Discussion Topics 08/16/2014 11:23:05 $VRNG did you

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
VRNG Discussion Topics 08/16/2014 11:23:05 $VRNG
did you really think vrng had any chance of winning? lol. joke
Right - another confirmation of NO REAL REVENUES!
No, I am not short. I just have a grasp for the obvious shortcomings of the company. First & Foremost, I would NEVER have paid $3 for a stock with a true share value in the .025 - .55 range. PLUS, I see SERIOUS issues with this company's FUTURE revenues. I hope they can show revenues from something other than lawsuits.
VRNG still received several search patents from the Microsoft deal so all was not lost on that deal.
RD,

I hope you didn't go short on Friday after the news. The bottom has already been put in at $.67; next week we will start trending up to the $1.40-$1.60 range while we wait for news. If news or updates hit, then bumping up against $2.00/share is not out of the question. You sound like someone desperate. If someone was short VRNG from the $3.00 range and is still holding, then they are hyper-greedy, and a bit unwise, and deserve to lose some money when the share price heads up. I suspect the wise, savvy shorts have covered or will be covering en masse on Monday. They made a ton of money; sticking around here for a few more pennies is hardly worth their time, especially with the upside potential of the stock at these levels. Again, if you went short Friday after the news, have fun with that.

Tink

Yes, that's a GOOD idea. Current Technology makes old patents antiquated. IMO they are worthless. That is why Nokia sold them. Hint Hint
Don't forget VRNG still has a law suit against Asus. Also, most likely if ZTE settles then the next companies to go after could be Huawei or HTC.
Two thoughts

2)VRNG legal team never put a foot wrong.. throughout the past 2 years they have done nothing but win.. so they lost the big one and yes that bites hard.. but that doesn't mean the legal team is any less proficient at what they do .. if anything it points to some serious failings in the US Legal system.

3) VRNG locked in a cash and patents deal with MSFT on patents which were ruled to be invalid.. (not a bad score for some so called invalid patents)


Quote:
2)Laches blindside was a bad move, not arguing against laches when they had their chance.

3)Microsoft payment is a percentage of what Google pays. Right now google is paying zero. Microsoft pays a percentage of zero which will always be zero.


ok its time to look at the positives..

1) VRNG share price is currently lower than the avg price pre merger with innovate and protect... that is back when it was a video ringtones software company that was losing money and didn't have a huge warchest of patents.

2) VRNG legal team never put a foot wrong.. throughout the past 2 years they have done nothing but win.. so they lost the big one and yes that bites hard.. but that doesn't mean the legal team is any less proficient at what they do .. if anything it points to some serious failings in the US Legal system.

3) VRNG locked in a cash and patents deal with MSFT on patents which were ruled to be invalid.. (not a bad score for some so called invalid patents)

4) VRNG still hase a huge box of Nokia patents... not software related and not so obvious and therefore not likely to be subject to the same fate as the IP Engine patents.

5)If VRNG does not take this to the supremes then cash burn will be reduced dramatically.. if they do then some limited faith will be restored in the stock.


so to me at 88c the stock looks oversold... does that mean it can recover some of its lost ground? well that depends on the shorts.

but that being said, shorts really don't have much reason to stick around now because they already hit the jackpot on the big binary event... and there really aren't any other binary events that can go against vrng that are of the same magnitude.

so i'm going to go out on a limb here and call bottom somewhere around 60-80c

given that we still have 30+ million in the bank and the 1 billion plus royalties from goog were never factored in to the share price I'm going to split the baby and say we should be looking at a price target of between 1.20-1.50 per share which is in line with what some others have suggested.



SQ COMING TO VRNG.... WATCH FOR NEW$$$$$



Yeah, Smart Money, I agree.

There's just too much fiction and nonsense being tossed around. Which is pretty disappointing since real people have lost a lot of money on VRNG this past week.

Inventors can't patent wireless communications as they apply to the standards?

Yet companies like Qualcomm, InterDigital, Nokia, Ericsson, etc. have been collecting billions of dollars in revenues from wireless patents since the 1980s!!!

Click, poof, gone. I won't be responding to trolls anymore.
$1.20-1.50


LOVE THE CLOSE ON FRIDAY, AND EVEN MORE SO A/H

SHOWING MUCH STRENGTH THAT .67 WAS BOTTOM, AND ANYTHING UNDER A BUCK IS A NOW BRAINER!!

GET READY TO AVG UP ON YOUR SHORT POSITION/PUTS


Patent Infringement? What will Vringo do for revenue when they run out of people to sue??
Yes, the judgement is showing on their Accounts Receivable, if not in cash!
You cant patent a wireless standard!
Actually, you are wrong. If the patent applies to a common function, in a larger service field, then it is a worthless patent. Or, if technology is so Outdated that a company decides to sell it!

Yea...Probably not.
you are confused on so many things

1) wireless standards are not open source
2) the wireless/mobile patent portfolio has nothing to do with the patents invalidated in the Google appeal
3) judgements won't be refunded because there is nothing to refund - no payment has actually been made by Google

patent infringement is very different than filling out a Form 1040EZ and about a million times more complex


Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 150

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading

Top 5 Most Recently Viewed Articles

Japan's Economic Outlook Dims as Export Weakness Persists

Updated Category News Views 189

Japan's Revised Economic Growth Forecast Recently, Japan's government announced a downward revision of its GDP growth forecast for the current fiscal year. This adjustment is significant as it reflects the ongoing struggles within the economy, particularly in light of weaker export performance that is hindering a fragile recovery. Details on the Growth Projection The...

Continue Reading
The Importance of Employee Recognition in the Workplace

Updated Category News Views 254

The Importance of Employee Recognition in the Workplace Gratitude is a key theme during Thanksgiving, but in the workplace, recognition for employee contributions plays an equally significant role throughout the year. As companies strive to enhance their workplace culture, the value of recognizing employees cannot be overstated. Understanding Employer Perspectives A...

Continue Reading
Class Action Alert for Shareholders of Orthofix Medical

Updated Category News Views 196

Class Action Lawsuit Overview In the current landscape of securities litigation, investors in Orthofix Medical, Inc. have a critical opportunity to engage with a class action lawsuit that addresses significant issues of corporate governance and transparency. This legal action has arisen following severe corporate management changes that have caused share price...

Continue Reading
Understanding Recent Trends in Lowe's Short Interest

Updated Category News Views 107

Understanding Lowe's Companies' Short Interest Lowe's Companies (NYSE: LOW) has seen its short percent of float decrease by 12.78% since the last report. Currently, there are approximately 6.55 million shares sold short, which constitutes 1.16% of all shares available for trading. Given the current trading volume, it would take traders about 2.91 days to cover their short...

Continue Reading
YD Bio Limited and EG Biomed Enhance Clinical Testing with CAP Accreditation

Updated Category News Views 151

Transformative Advancements in Clinical Testing by YD Bio Limited YD Bio Limited, a pioneering biotechnology company known for its advancements in DNA methylation-based cancer detection, recently celebrated a significant milestone through its collaboration with EG Biomed US Inc. This partnership has propelled forward the capabilities of clinical testing, particularly in...

Continue Reading